中風病人糖尿病之藥物治療及其心血管保護效果：GLP-1 RA與SGLT2i之更新回顧

Pharmacotherapy and Cardiovascular Protection for Diabetes in Stroke Patients: An Updated Review of GLP-1 RA and SGLT2i

謝鎮陽(Cheng-Yang Hsieh) ； 田凱仁(Kai-Jen Tien)

《台灣中風醫誌》 4卷1期 (2022/03) Pp. 1-13

https://doi.org/10.6318/FJS.202203_4(1).0001

並列摘要

In 2008, the U.S. Food and Drug Administration issued a mandate that cardiovascular outcome trials (CVOTs) should be performed for all novel antidiabetic drugs to confirm their cardiovascular safety. Since that, more than 200,000 patients have been enrolled in more than 20 CVOTs. Unexpectedly, two classes of these novel antidiabetic drugs, that is, glucagon-1like peptide-1 receptor agonists (GLP-1 RA) and sodium glucose cotransporter 2 inhibitors (SGLT2i), not only had cardiovascular safety, but also were proven to be effective in reducing major adverse cardiovascular events (including non-fatal stroke) or hospitalization for heart failure. In this review, we aimed to update the cardiovascular evidences regarding GLP-1 RA and SGLT2i for physicians taking care of stroke patients with diabetes in their daily practice.

並列關鍵字

Diabetes ； MACE ； stroke ； SGLT2 inhibitor ； GLP-1 RA